Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21

Department of Gastroenterology and Hepatology, BNHFT Hospital Basingstoke, Aldermaston Road, Basingstoke RG24 9NA, UK
British Journal of Cancer (Impact Factor: 4.84). 02/2011; 104(4):587-92. DOI: 10.1038/sj.bjc.6606086
Source: PubMed


Quality of life measurement in cholangiocarcinoma and gallbladder cancer involves the assessment of patient-reported issues related to the symptoms, disease and treatment of these tumours. This study describes the development of the disease-specific quality of life (QoL) questionnaire for patients with cholangiocarcinoma and gallbladder cancer to supplement the European Organization for Research and Treatment of Cancer (EORTC)-QLQ C30 core cancer questionnaire.
Phases 1-3 of the guidelines for module development published by the EORTC were followed, with adaptations for incorporation of questions from existing modules.
A total of 47 QoL issues (questions) were identified; 44 questions from the two related validated questionnaires, the EORTC QLQ-PAN26 (pancreatic module) and the EORTC QLQ-LMC21 (liver metastases module), two from the Functional Assessment of Cancer Therapy hepatobiliary module questionnaire in the literature search and one from healthcare professional interviews. Following phase 1 and 2 interviews with patients (n=101) and health care professionals (n=6), a 23-question provisional questionnaire was formulated. There were five questions from PAN26, 15 from LMC21 and three extra questions. In phase 3, the provisional item list was pre-tested in 52 patients in four languages and this resulted in a 21-item module.
This is the only disease-specific QoL questionnaire for patients with cholangiocarcinoma and gallbladder cancer, and initial assessments show it to be accurate and acceptable to patients in reflecting QoL in these diseases.

Download full-text


Available from: Ghasem Yadegarfar
  • Source
    • "Few studies have evaluated it in patients with malignant biliary obstruction, and variable methodology and scores were employed. Only recently a specific European Organization for Research and Treatment of Cancer[EORTC]questionnaire for biliary tumors has been implemented, QLQ-Bil 21[23], and we await results on its applicability in everyday clinical experience. Measurement of quality of life does not include only relief of itching and cosmetic effects on jaundice, but also the consequences of the disease on physical, relational and emotional well-being. "

    Full-text · Article · Jan 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biliary tract cancers (BTCs) encompass different cancers: intrahepatic, Katskin tumor, gallbladder, and main bile duct cancer. Surgical management of these cancers is difficult and most patients with BTC are likely to present with an unresectable or metastatic disease. Although standard systemic chemotherapy approaches are emerging, the prognosis remains poor. Development of adaptive therapeutic strategies is ongoing, as a better knowledge about these tumors is emerging.
    No preview · Article · Mar 2012 · Oncologie
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: It is critical for gastrointestinal cancer researchers and clinicians to have access to comprehensive, sensitive and simple-to-use symptom measures that allow them to understand and quantify the subjective patient experience. Development and validation of such scales requires training in psychometrics and occasionally uses technical jargon that can be difficult to penetrate. This review evaluates existing measures of gastrointestinal cancer symptoms, provides tool descriptions, and uses predefined, objective quality criteria to rate psychometric quality and facilitate tool choices for researchers and clinicians. Methods: MEDLINE, EMBASE, CINAHL, and PsycINFO databases were systematically reviewed for scales assessing gastrointestinal cancer and gastrointestinal cancer site-specific symptoms. Evaluation criteria were the following: breadth of domain coverage (content validity), high internal consistency (α ≥ .80), sensitivity to change, and extent of validation. Results: In n = 36 validation studies, 26 gastrointestinal cancer symptom measures were identified. Of these, n = 13 tools met criteria for recommendation, and six in particular showed strong psychometric properties. The Functional Assessment of Cancer Therapy-Colorectal (FACT-C), European Organization for Research and Treatment of Cancer (EORTC) gastric cancer module (QLQ-STO22), FACT-Hepatobiliary (FACT-Hep), and EORTC oesophagus, oesophago-gastric junction and stomach module (QLQ OG-25) were identified as the most comprehensive and best validated scales for each of the major gastrointestinal cancer sites. The FACT-Colorectal Symptom Index (FCSI-9) and the National Comprehensive Cancer Network (NCCN) FACT-Hepatobiliary Symptom Index (FHSI-18) were specifically validated in patients with advanced colorectal and liver cancer and also demonstrated superior psychometric properties. Conclusions: Several comprehensive, well-validated scales exist to adequately assess gastrointestinal cancer site-specific symptoms. Specifically, gastrointestinal cancer submodules of the FACT quality of life questionnaire represent adequate tool choices in most instances and overall, were better validated than the respective EORTC tools. Further improvement of existing, highly rated measures is recommended.
    Full-text · Article · May 2014 · Supportive Care Cancer